Quantbot Technologies LP Acquires 4,397 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Quantbot Technologies LP increased its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 189.9% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 6,712 shares of the company’s stock after purchasing an additional 4,397 shares during the period. Quantbot Technologies LP’s holdings in Medpace were worth $2,764,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of MEDP. Private Advisor Group LLC acquired a new stake in shares of Medpace in the fourth quarter valued at about $296,000. Principal Securities Inc. bought a new position in Medpace during the 4th quarter worth approximately $68,000. Vanguard Personalized Indexing Management LLC lifted its position in shares of Medpace by 91.7% in the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 3,149 shares of the company’s stock worth $965,000 after purchasing an additional 1,506 shares during the period. Janney Montgomery Scott LLC boosted its stake in shares of Medpace by 40.9% in the 4th quarter. Janney Montgomery Scott LLC now owns 7,098 shares of the company’s stock valued at $2,175,000 after purchasing an additional 2,061 shares during the last quarter. Finally, Level Four Advisory Services LLC increased its position in shares of Medpace by 10.6% during the fourth quarter. Level Four Advisory Services LLC now owns 1,744 shares of the company’s stock worth $535,000 after buying an additional 167 shares during the period. 77.98% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have commented on MEDP. Mizuho initiated coverage on shares of Medpace in a research report on Tuesday, May 28th. They set a “buy” rating and a $435.00 price target on the stock. TD Cowen decreased their target price on Medpace from $452.00 to $434.00 and set a “buy” rating for the company in a research note on Wednesday, July 24th. StockNews.com raised Medpace from a “hold” rating to a “buy” rating in a research note on Thursday, September 5th. Deutsche Bank Aktiengesellschaft reduced their price objective on shares of Medpace from $395.00 to $336.00 and set a “hold” rating for the company in a research report on Wednesday, July 24th. Finally, William Blair reissued an “outperform” rating on shares of Medpace in a research note on Wednesday, September 11th. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $423.00.

Medpace Stock Down 0.6 %

Medpace stock opened at $354.65 on Wednesday. The stock has a market cap of $10.99 billion, a price-to-earnings ratio of 36.15, a PEG ratio of 1.74 and a beta of 1.36. The business has a 50-day simple moving average of $382.17 and a 200 day simple moving average of $392.66. Medpace Holdings, Inc. has a 52 week low of $227.21 and a 52 week high of $459.77.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Monday, July 22nd. The company reported $2.75 earnings per share for the quarter, beating the consensus estimate of $2.54 by $0.21. Medpace had a net margin of 16.74% and a return on equity of 55.14%. The firm had revenue of $528.10 million for the quarter, compared to analysts’ expectations of $528.41 million. During the same quarter last year, the company posted $1.93 EPS. The business’s quarterly revenue was up 14.6% on a year-over-year basis. On average, research analysts anticipate that Medpace Holdings, Inc. will post 11.66 earnings per share for the current year.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.